Treatment and outcomes of SLE patients with TMA.
| Variables | ADAMTS13 Inhibitor − negative, n = 13 | ADAMTS13 inhibitor−positive, n = 6 | ADAMTS13 inhibitor (+)/(−), HR (95% CI) | p |
|---|---|---|---|---|
| Therapies | ||||
| TPA, n | 13 (100.0) | 3 (50.0) | 0.021 | |
| No. TPA sessions, n | 5.0 (3.5–8.5) | 2.0 (0.0–8.2) | 0.628 | |
| Steroid pulse therapy, n | 10 (76.9) | 5 (83.3) | 1.000 | |
| Immunosuppressants, n | 13 (100.0) | 6 (100.0) | 1.000 | |
| IVIG, n | 10 (76.9) | 3 (50.0) | 0.320 | |
| Therapeutic responses | ||||
| Followup, mos | 5.9 (1.5–10.9) | 4.4 (2.5–7.4) | 0.620 | |
| Complete remission | 3 (23.1) | 6 (100.0) | 10.8 (1.8–65.5) | < 0.001 |
| Partial remission | 6 (46.1) | 6 (100.0) | 6.9 (1.3–37.4) | < 0.001 |
| Social economy | ||||
| Hospitalization days | 45.1 ± 13.4* | 30.5 ± 3.4 | 0.005 | |
| Hospitalization cost, × CNY1000 | 151.0 ± 78.5 | 61.3 ± 44.2 | 0.019 |
Values are expressed as the mean ± SD or median (interquartile range) unless specified. Attribute values are expressed as number (percentage). Significant p values are in bold face.
↵* One patient died on Day 17 and one on Day 33 of hospitalization, and they were not included in the analysis. SLE: systemic lupus erythematosus; TMA: thrombotic microangiopathy; CNY: Chinese yuan; IVIG: intravenous immunoglobulin; TPA: therapeutic apheresis.